Although statins reduce the risk of non-haemorrhagic strokes and transient ischaemic attacks (TIA), little is known about the efficacy of fibrates. This situation has been partly remedied by the recent publication of two-fibrate based trials -The Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial (VAHIT) and the Bezafibrate Infarction Prevention Trial (BIP). In BIP, bezafibrate did not significantly reduce the risk of a cerebrovascular event (CVE). Bezafibrate increased the high density lipoprotein cholesterol (HDL) level by 18% to 40 mg / dl (1.03 mmol / l) and decreased triglyceride (TG) levels by 21% to 115 mg / dl (1.29 mmol / l). In contrast, in VAHIT, gemfibrozil significantly reduced the risk of investigators designated stroke (P50.04) and TIA (P,0.001). Gemfibrozil increased HDL by 6% to 33 mg / dl (0.85 mmol / l) and decreased TG by 31% to 110 mg / dl (1.25 mmol / l). However, the baseline low density lipoprotein cholesterol (LDL) levels were higher in BIP than in VAHIT (148 versus 111 mg / dl; 3.82 versus 2.87 mmol / l). LDL levels were not markedly altered by treatment in either trial. Fibrates can improve several CVE predictors, like fibrinogen, lipoprotein (a), insulin sensitivity and platelet activity. Furthermore, lowered HDL and / or raised TG levels are associated with an increased risk of a CVE; fibrates are an appropriate treatment for this lipid profile. In conclusion, the evidence suggests that not only total cholesterol and LDL, but also HDL and TG levels predict the risk of a CVE. Statins, fibrates or a combination of these drugs can modify these variables.
Introduction
stroke relationship. For example, low levels of TC represent an increased risk of haemorrhagic stroke [30, 31] . This There is evidence (epidemiological and trialdual effect may explain why early epidemiological surveys based) supporting an association between elevated serum and clinical trials did not detect a consistent association total cholesterol (TC) and low density lipoprotein cholesbetween TC and non-haemorrhagic1haemorrhagic strokes terol (LDL) levels and the risk of thrombotic (non-haemorconsidered together [1, 17] . Furthermore, stroke is a rhagic) stroke. Epidemiological studies have also linked heterogeneous condition. For example, atrial fibrillation or low serum levels of high density lipoprotein cholesterol cerebral small vessel disease may cause some strokes but (HDL) with the risk of a cerebrovascular event (CVE) dyslipidaemias do not necessarily play a causal role in [1] [2] [3] [4] [9] [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] [22] [23] . In contrast, there is relatively less these conditions. Unlike IHD, thrombotic stroke is mainly evidence supporting a causative role for triglycerides (TG) .
a disease of the elderly [3] . It follows that some patients All these links are both complex and weaker [4] than those with IHD will have died or benefited from lipid lowering seen between these lipid variables and ischaemic heart prior to reaching old age and an increased risk of having a disease (IHD).
CVE. A further problem is that lipid variables alter with Several factors influence the strength of the lipidsaging [1, 32] ; this may weaken the relationship between lipids and stroke. Time for primary review 28 days.
As a result of these limitations, if stroke is considered as HDL levels in the top quintile were associated with a a single entity, inconsistent results may be generated significant 50% reduction in the risk of nonfatal stroke regarding the predictive value of any risk factor. This compared with men in the lowest quintile for HDL values. disadvantage can be overcome because it is now possible As expected, the presence of IHD (24.4% of the to differentiate the type of stroke by using imaging subjects) or diabetes (1.4% of the subjects) was associated techniques. However, many epidemiological studies and with an increased risk of a CVE. A trend for a protective clinical trials did not benefit from this classification.
effect of HDL levels was evident within the IHD group The link between elevated TC levels and the risk of and smokers. non-haemorrhagic stroke or transient ischaemic attacks (TIA) is reinforced by the findings of several trials that 2.2. The Israeli ischaemic heart disease study [10] assessed the effect of statins in patients with IHD [1, [5] [6] [7] [8] 18, [24] [25] [26] [27] [28] [29] . This benefit was limited to nonfatal and This prospective study included 8586 men (.42 years) non-haemorrhagic stroke (approximately a 30% decrease in followed up for 21 years. The end point was fatal risk). The primary prevention trials involving statins ischaemic stroke. Stroke type was determined on clinical showed a similar trend, but this did not achieve statistical grounds. Therefore, some degree of misclassification may significance [33, 34] [11] The association between lipid levels and the risk of In this Finnish study, 28,519 men, aged 50-69 years, stroke has been reviewed elsewhere [1, 8] . Here we consiwere followed up for 6 years. All those included in the der recent major prospective epidemiological studies that study were smokers and none had a previous stroke. The highlight the role of HDL and / or TG as CVE predictors.
end point was cerebral infarction and cerebral or subarachnoid haemorrhage. Most (85%) of the cases were diag-2.1. The British regional heart study [9] nosed using CT, MRI or angiography. Multivariate analysis showed a significant negative In this prospective study, 7735 men (40-59 years old) association between HDL and cerebral infarction or were followed up for 16.8 years. The end point was fatal subarachnoid haemorrhage. No relation between HDL and or nonfatal stroke. No information on the type of stroke intracerebral haemorrhage was found. Serum TC was was available.
inversely correlated with the risk of intracerebral haemorMultivariate analysis revealed a significant negative rhage whereas the risk of cerebral infarction was increased association between HDL levels and nonfatal stroke. The at TC levels .7.0 mmol / l (270 mg / dl). adjusted relative risk (RR) for nonfatal stroke was 0.59 (95% confidence interval, CI,50.39-0.90; P50.03) when 2.4. The Dubbo study [12] comparing the top and the lowest HDL quintiles. For fatal stroke, there was no significant association with HDL. This This Australian prospective study included 2805 elderly lack of significance may reflect the small number (n560) (.60 years; mean age 69 years) men and women followed of fatal events. The TC and non-fasting TG levels were not up for 98 months. The end point was ischaemic stroke and significantly related to fatal or nonfatal stroke. However, TIA. Most of the strokes (70%) were diagnosed using CT. elevated TC levels showed a trend for an increased risk of There were few (n529) haemorrhagic strokes. These were stroke.
not included in the analysis. In hypertensives (approximately 34.5% of the subjects), Multivariate analysis revealed a significant negative association between HDL and all strokes (fatal, nonfatal (11,342 versus 2723) and cases (279 versus 99) than the and TIA) as well as between HDL and fatal strokes. There
Framingham study [37] . was a 36% reduction in risk for a 1.0 mmol / l (39 mg / dl)
In another analysis from Framingham [16], 1116 men increment in HDL. There was no association between and women free of cardiovascular disease, aged 66-93, fasting TG and strokes. In comparison, a previous stroke were studied prospectively for 12 years. TC levels (no conferred a 227% higher risk of a subsequent CVE. Atrial evidence for HDL), but not TG, were positively associated fibrillation and the highest category of blood pressure with ultrasonographic evidence of carotid atherosclerosis reading were associated with a 58 and a 67% higher risk of [16] . stroke, respectively.
A meta-analysis [17] of 45 prospective observational cohorts (450,000 individuals) found no association between TC and stroke. However, there was no separation of 2.5. The Copenhagen study [13] the types of stroke. Therefore, the lack of any overall relation might conceal a positive association with isIn this prospective study, 19,698 men and women were chaemic stroke and a negative association with haemorfollowed up for 12 years. The end point was cerebral rhagic stroke. infarction, TIA and cerebral haemorrhage. The diagnosis
In the Atherosclerosis Risk In Communities (ARIC) [38] was made using CT or brain autopsy in 40% of cases. The study, 12,205 men and women, aged 45-64 were evaluremaining events were classified as unspecified and were ated for symptoms of stroke and TIA through a quespresumed to be mostly ischaemic.
tionnaire and data were collected on HDL, LDL, and TG A significant negative association was shown between levels. No relation was found between these lipid values HDL and ischaemic strokes; the decrement in RR per 1.0 and stroke / TIA symptoms. However, it may be relevant mmol / l (39 mg / dl) rise in HDL was 47%. TC was that the evaluation of stroke was made using a quespositively associated with the risk of non-haemorrhagic tionnaire. events, but only for levels .8.0 mmol / l (310 mg / dl). Additionally, TG levels (non-fasting) were significantly associated with the risk of ischaemic strokes. The RR increment was 1.12 (95% CI51.07-1.16) per 1.0 mmol / l 4. HDL and TG levels as targets for CVE prevention (88.5 mg / dl) increase in TG.
The evidence described above suggests the need to increase HDL and decrease abnormal TG levels to prevent 2.6. The Finnmark study [14] stroke / TIA. These objectives could be accomplished by using fibrates but there are no trials that specifically In this Norwegian study, 13,266 men and women, aged evaluate the protection from strokes using these drugs. 35-52 years, were followed up for 14 years. The end point However, two trials, the Veterans Affairs High-Density was fatal or nonfatal stroke.
Lipoprotein Cholesterol Intervention Trial (VAHIT) [35] There was a significant association between non-fasting and the Bezafibrate Infarction Prevention Trial (BIP) [36] , TG and strokes, but only for women [RR51.29 per 1.0 assessed the contribution of low HDL levels (and TG mmol / l (88.5 mg / dl) increase in TG]. HDL was measured levels at the upper limit of the reference range) on the risk only at the second screening (three years after the beginof vascular events in patients with established IHD. ning of the study) in a sub-population of 11,286 men and women. There was an inverse relationship between HDL and stroke, but this association was not significant. 4.1. The VAHIT study [35] In this double blind study conducted in the USA, 2,531 3. Other epidemiological studies men with IHD received gemfibrozil 1200 mg or placebo. Mean follow up was 5.1 years and the primary end point In the Multiple Risk Factor Intervention Trial (MRFIT) was nonfatal myocardial infarction (MI) or death due to [15, 30, 31] , 353,340 men were followed up for 12 years. coronary causes. Gemfibrozil increased HDL levels by 6% TC was positively associated with death from non-haemor-(32-33.2 mg / dl; 0.82-0.85 mmol / l), reduced TG levels rhagic stroke and inversely associated with intracranial by 31% (161-110 mg / dl; 1.81-1.25 mmol / l); LDL levels haemorrhage. These authors did not comment on HDL remained unaltered (111 mg / dl; 2.87 mmol / l). The reduclevels.
tion in the risk in primary end points (22%) and in all end In the Framingham [37] study, HDL had a non-signifipoints combined (nonfatal MI, death due to CHD and cant effect on the overall risk of stroke in both men and stroke) was 24%; both these results were significant (P5 women and on ischaemic stroke in men. This apparent 0.006 and P,0.001, respectively). discrepancy may be attributed to the 'study size'. For
Regarding stroke / TIA, the outcome was also favorable example, the Copenhagen study [13] had more subjects (Table 1) . [36] did not confirm this Therefore, the profile of the patients in VAHIT was more assumption. However, BIP [36] and VAHIT [35] differ in appropriate for the use of a fibrate. The mean LDL value in several ways. These differences could account for the VAHIT (111 mg / dl, 2.87 mmol / l) was near the guideline apparent discrepancy in outcome regarding stroke and target values for patients with IHD [35] (100 mg / dl; 2.6 IHD-related events. mmol / l for the USA and 115 mg / dl; 3.0 mmol / l for the The incidence of the primary end point was greater in UK). In contrast, the mean LDL in BIP (148 mg / dl; 3.82 VAHIT [35] (22%) than in BIP [36] (15%). There are mmol / l) was above these target values. This suggests that several reasons for this difference. In VAHIT [35] , more a statin could have been a more appropriate choice in BIP. patients were: men (100 versus 91%), older (mean age 64 Some of the reasons mentioned above may explain why 2 there are more investigator designated strokes (x test1 Yates' correction: P50.035) in the VAHIT placebo group Table 2 when compared with the corresponding group in BIP a Cerebrovascular events in BIP (Tables 1 and 2 ). This difference is present despite the fact Bezafibrate Placebo P-value that VAHIT was of a shorter duration (Tables 1 and 2 were 9.9 strokes / 1000 patients / year in the treatment group in VAHIT, compared to 7.5 strokes / 1000 patients / year in been used. These differences in potentially clinically BIP (a 24% relative increase in strokes). However, comrelevant properties raise the question 'are all fibrates parisons are limited by the design differences in both trials equally effective?' (see above). For example, the mean age of patients was Platelet inhibitors prevent strokes and TIA [49, 50] . In greater in VAHIT than in BIP (64 and 60 years, at baseline this context, there is evidence that fibrates and statins and 69.1 versus 66.2 years at the end of the trials).
reduce platelet activity [49] . This may be an additional Accordingly, age confers a greater CVE risk in VAHIT.
beneficial action of these drugs. Furthermore, there was no distinction between haemorLipoprotein (a) [Lp(a)] is thought to contribute to rhagic and ischaemic stroke in both trials. In addition, the atherogenesis (by transporting LDL molecules and inincidence of TIA, which are strongly linked with isfluencing vascular smooth muscle proliferation), to inhibit chaemic events, were significantly (P,0.001) reduced in fibrinolysis (because of a structural analogy with plas-VAHIT but are not documented in BIP. minogen) and possibly to influence platelet function [2, 51] . One possible conclusion based on the findings of both Epidemiological studies suggest that elevated serum Lp(a) VAHIT and BIP is that when serum LDL levels reach a levels are associated with an increased risk of stroke and satisfactory value, altering HDL (and possibly TG) levels carotid disease [2, [51] [52] [53] . The link between Lp(a) and results in a significant reduction in the risk of vascular vascular risk appears to be magnified when other carevents. This interpretation is compatible with the findings diovascular risk factors are present [52] . In addition, some of early trials involving lipid lowering drugs (or dietary but not all, studies have shown a correlation between the intervention) [1, 17, [24] [25] [26] [27] [28] [29] since LDL levels were not circulating levels of Lp(a) and fibrinogen [46] . Lp(a) levels markedly reduced in these trials. This may be the reason were not reported in VAHIT, BIP or for that matter in most why they did not show any benefit in terms of stroke of the major statin-based prevention trials [5] [6] [7] [33] [34] [35] [36] . prevention. These early (pre-statin) trials had several This is unfortunate because there is some evidence showadditional limitations. For example, there was no differening that fibrates can lower raised Lp(a) levels [45, 46] . In tiation between haemorrhagic and non-haemorrhagic contrast, there is evidence that some statins may slightly strokes. Furthermore, overviews of these early trials pooled raise the serum levels of this lipoprotein [45, 46, 54] . results from studies that involved patients with and without Diabetes and impaired insulin sensitivity represent a IHD [1] .
considerable increment in vascular risk (including stroke and TIA) [55] . For example, in the Helsinki Policemen study [56] , the age-adjusted hazard ratio (22 year follow 6. Are the additional actions of fibrates relevant? up) for 'insulin resistance' was 1.64 (95% CI51.29-2.08) with regard to stroke risk. 'Insulin resistance' was a less Fibrinogen [19, 20, [39] [40] [41] is a powerful and independent powerful risk factor for IHD [1.28 (95% CI51.1-1.5)]. predictor of vascular events in healthy individuals and
The ARIC study also showed that glucose levels in nonpatients with vascular disease. Elevated levels of this diabetics predicted stroke [21] . This finding probably coagulation factor are also associated with the progression represents a causative role for insulin resistance [21, 22] . of carotid artery disease [42] . Furthermore, when low There are no intervention trials specifically assessing the levels of HDL are combined with high fibrinogen levels, effect of fibrates or statins in patients with diabetes or ultrasound examination shows that the association with insulin resistance. We need to await the outcome of carotid artery disease is strengthened [42] . There are no ongoing trials. However, the results from patient subdrugs that selectively lower plasma fibrinogen levels groups included in secondary prevention trials using [39, 40] . Therefore, it may never be possible to prove that pravastatin, simvastatin or gemfibrozil are encouraging in lowering the circulating levels of fibrinogen is beneficial terms of reducing the risk of vascular events in diabetics [39, 40] . The best available trial-based evidence comes and patients with insulin resistance [57, 58] . Fibrates may from BIP [43] where elevated fibrinogen levels were be ideally suited for patients with non-insulin dependent associated with a greater risk of vascular events. Of greater (Type 2) diabetes because the main lipid abnormality is interest were the results within the group of patients who low HDL and raised TG levels [57, 59] . Furthermore, initially had the highest plasma fibrinogen levels [43] .
fibrates increase insulin sensitivity, although this is a There were significantly fewer events in those who then relatively minor effect [44] [45] [46] [47] [48] 57] . showed a fall in the levels of fibrinogen when compared
Fibrates can exert unwanted effects. For example, with those patients that did not show such a fall [43] .
fibrates can raise the plasma levels of homocysteine (Hcy) Another potentially relevant factor when considering fiprobably by interfering with the renal excretion of Hcy brinogen is that gemfibrozil, unlike the other fibrates (e.g. [60] . Such an effect may be relevant because elevated bezafibrate, ciprofibrate and fenofibrate), may not conplasma Hcy levels have been associated with an increased sistently lower plasma fibrinogen levels [44] [45] [46] [47] [48] . Thererisk of stroke (and other vascular events) [52, 61] . This fore, it is possible to speculate that the VAHIT results effect may be especially relevant in patients who tend to would have been even more impressive had another fibrate have elevated plasma Hcy levels and a high risk of a CVE (e.g. those with peripheral vascular disease) [60] . Statins occurred in the past, especially concerning lipid lowering, do not appear to adversely affect Hcy levels [60] .
because the association between dyslipidaemia and risk of The additional actions of fibrates described above are stroke or TIA was not widely appreciated [1] . Such an scientifically credible but a definitive judgement on their intervention may be useful since the need for carotid clinical relevance must await trial-based evidence.
endarterectomy was significantly (P,0.001) decreased in the treatment group in VAHIT [35] . Regarding carotid surgery, it is also relevant to consider that some risk 7. Interactions between lipids and other factors that factors for carotid artery disease progression [e.g. lipids, are associated with an increased risk of a CVE fibrinogen and Lp(a)] [1, 2, 42, 51, 53, 71, 73] are also associated with an increased risk of restenosis in coronary and Cardiovascular risk factors may be considered in isolaperipheral arterial grafts [70] . tion. This is unacceptable because these factors act synerDespite these well-documented interactions, many epigistically and tend to cluster [62] . Furthermore, one risk demiological surveys and drug trials did not include the factor may adversely affect another. For example, measurement of several risk factors. dyslipidaemias adversely affect platelet activity and this effect may be reversed by lipid lowering agents [49] . Smoking, obesity and insulin resistance raise fibrinogen levels [39, 40, 55] . Although serum Lp(a) levels are largely 8. Mechanisms that may be responsible for the genetically determined, the circulating levels of this decrease in CVE risk provided by lipid lowering lipoprotein rise after the menopause [63] . It is at this time agents that the cardiovascular risk of women becomes similar to that of men [63] . It is therefore of interest that the Lipid lowering drugs improve atherosclerosis as asmenopause is also associated with a rise in plasma sessed by carotid angiography, duplex scanning [71] and fibrinogen levels and adverse changes in the lipid profile intima-media thickness (IMT) measurements [60] . The [32, 39, 40, 55] . Smoking is associated with several adverse IMT is a predictor of stroke, TIA and IHD [72] . Prelimineffects. These include a fall in HDL and a rise in TG and ary results suggest that the effect of statins on the IMT fibrinogen levels as well as an increase in insulin resistance may be very rapid (within 8 weeks) [60] . This may [55]. Diabetics have a higher incidence of hypertension represent an anti-inflammatory action [60] . and dyslipidaemia [57] . Hypertension, a major CVE risk Improving the lipid profile is associated with plaque factor, usually occurs in conjunction with other risk stabilisation within the carotids and the aortic arch [71] . factors; only in 20% of patients does it occur in isolation These sites are the source of emboli that may cause a CVE. [62] . Thus, in hypertensives, clusters of three or more It is also relevant that carotid atherosclerosis is not only additional risk factors (e.g. raised TG and reduced HDL associated with elevated LDL levels but also with dilevels) occur at four times the rate expected by chance minished HDL levels and hypertriglyceridaemia [62] . This clustering is attributed to insulin resistance [62] .
[16, 73, 74] . Based on the Framingham study, the prevalence of insulin Low levels of HDL and high TG levels are risk factors resistance in the general population could be as high as for peripheral arterial disease and IHD [75] . In turn, these 22% in men and 27% in women [62] .
patients are more likely to have a CVE [75] . This increased The presence of vascular disease (e.g. IHD) itself risk may relate to the extent of vascular damage and any increases the probability of strokes [1] . Therefore, it is concomitant inflammatory response. These changes are worth noting that some models [64] for IHD and CVE risk associated with platelet activation, as well as elevated estimation include TG and HDL levels. Furthermore, fibrinogen and C-reactive protein (CRP) levels [76] . All prediction equations for several vascular end points demthese variables may be influenced by lipid lowering onstrated the potential importance of controlling multiple therapy [49] . risk factors [65] , as opposed to focusing on a single risk Fibrates are peroxisome proliferator-activated receptors factor.
( Smoking reduces the overall benefit derived from statins haemostatic factors [43, 49, 54, 59, 67, 68] .
but the effect on the risk of stroke was not analyzed The role of carotid endarterectomy in stroke prevention separately [78] . Thus, in the major statin trials, treatment has not been fully defined [69] . However, when comparing was associated with a significant reduction in events in surgery with medical treatment it is important to always smokers but the best outcome was observed in treated provide the best preventive measures. This may not have non-smokers [78] . However, the effect of smoking on
